Literature DB >> 32346887

Insulinoma-associated protein 1 is a prognostic biomarker in pulmonary high-grade neuroendocrine carcinoma.

Kazuhiro Minami1, Naoe Jimbo2, Yugo Tanaka1, Hiroyuki Ogawa3, Daisuke Hokka1, Wataru Nishio3, Masahiro Yoshimura3, Tomoo Itoh2, Yoshimasa Maniwa1.   

Abstract

BACKGROUNDS AND
OBJECTIVES: Recent studies have suggested that insulinoma-associated protein 1 (INSM1) is a useful marker for pathological diagnosis of pulmonary neuroendocrine tumors. In the present study, we investigated the association between INSM1 expression and prognosis in patients with pulmonary high-grade neuroendocrine carcinomas (HGNEC) and assessed the usefulness of INSM1 as a prognostic biomarker in these patients.
METHODS: Seventy-five consecutive patients with HGNEC who underwent complete surgical resections from January 2000 to December 2018 were enrolled in this study. We classified these patients into two groups: the INSM1-positive group (n = 59) and INSM1-negative group (n = 16). We compared the clinicopathological characteristics, overall survival (OS), and recurrence-free survival (RFS) between the groups. In addition, we performed univariate and multivariate analyses to identify the prognostic factors associated with postoperative survival.
RESULTS: Significant differences in tumor diameter and vascular invasion between the groups were found. OS and RFS were significantly poorer in the INSM1-positive group than in the INSM1-negative group. Univariate and multivariate analyses revealed that INSM1 expression was the strongest predictor of poor prognosis for OS and RFS.
CONCLUSIONS: INSM1 expression had the greatest influence on the prognosis in patients with HGNEC and may be a prognostic biomarker in these patients.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  immunostaining; insulinoma-associated protein 1; large cell neuroendocrine carcinoma; neuroendocrine markers; small cell lung carcinoma

Year:  2020        PMID: 32346887     DOI: 10.1002/jso.25960

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Overexpression of INSM1, NOTCH1, NEUROD1, and YAP1 genes is associated with adverse clinical outcome in pediatric neuroblastoma.

Authors:  Jasna Metovic; Francesca Napoli; Simona Osella-Abate; Luca Bertero; Cristian Tampieri; Giulia Orlando; Maurizio Bianchi; Diana Carli; Franca Fagioli; Marco Volante; Mauro Papotti
Journal:  Virchows Arch       Date:  2022-09-19       Impact factor: 4.535

2.  A promoter-driven assay for INSM1-associated signaling pathway in neuroblastoma.

Authors:  Chiachen Chen; Michael S Lan
Journal:  Cell Signal       Date:  2020-09-20       Impact factor: 4.315

3.  Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.

Authors:  Katharina Kriegsmann; Christiane Zgorzelski; Thomas Muley; Petros Christopoulos; Michael Thomas; Hauke Winter; Martin Eichhorn; Florian Eichhorn; Moritz von Winterfeld; Esther Herpel; Benjamin Goeppert; Albrecht Stenzinger; Felix J F Herth; Arne Warth; Mark Kriegsmann
Journal:  BMC Cancer       Date:  2021-05-01       Impact factor: 4.430

Review 4.  INSM1, a Novel Biomarker for Detection of Neuroendocrine Neoplasms: Cytopathologists' View.

Authors:  Zahra Maleki; Akash Nadella; Mohnish Nadella; Gopi Patel; Shivni Patel; Ivana Kholová
Journal:  Diagnostics (Basel)       Date:  2021-11-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.